Search Results - "Challice L. Bonifant"

Toxicity and management in CAR T-cell therapy by Bonifant, Challice L, Jackson, Hollie J, Brentjens, Renier J, Curran, Kevin J

“…T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). Most notably, CAR T cells have demonstrated…”
Get full text

Targeting glycans for CAR therapy: The advent of sweet CARs by Raglow, Zoe, McKenna, Mary Kathryn, Bonifant, Challice L., Wang, Wenjing, Pasca di Magliano, Marina, Stadlmann, Johannes, Penninger, Josef M., Cummings, Richard D., Brenner, Malcolm K., Markovitz, David M.

“…Chimeric antigen receptor (CAR) T cell therapy has created a paradigm shift in the treatment of hematologic malignancies but has not been as effective toward…”
Get full text

Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models by Mu-Mosley, Hong, Ostermann, Lauren, Muftuoglu, Muharrem, Vaidya, Abishek, Bonifant, Challice L, Velasquez, Mireya Paulina, Gottschalk, Stephen, Andreeff, Michael

“…Immunotherapy with T-cells expressing bispecific T-cell engagers (ENG T-cells) is a promising approach to improve the outcomes for patients with…”
Get full text

Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 costimulation by Vaidya, Abishek, Doherty, Erin, Wu, Xiya, Huang, Sujuan, Hebbar, Nikhil, Thanekar, Unmesha, Bonifant, Challice L, Cheng, Cheng, Gottschalk, Stephen, Velasquez, M Paulina

“…The outcome of patients with acute myeloid leukemia remains poor, and immunotherapy has the potential to improve this. T cells expressing chimeric antigen…”
Get full text

Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection by Christodoulou, Ilias, Rahnama, Ruyan, Ravich, Jonas W, Seo, Jaesung, Zolov, Sergey N, Marple, Andrew N, Markovitz, David M, Bonifant, Challice L

“…H84T-Banana Lectin (BanLec) CAR-NK cells bind high mannose glycosites that decorate the SARS-CoV-2 envelope, thereby decreasing cellular infection in a model…”
Get full text

The rapid and highly parallel identification of antibodies with defined biological activities by SLISY by Lu, Steve, Mattox, Austin K., Aitana Azurmendi, P., Christodoulou, Ilias, Wright, Katharine M., Popoli, Maria, Chen, Zan, Sur, Surojit, Li, Yana, Bonifant, Challice L., Bettegowda, Chetan, Papadopoulos, Nickolas, Zhou, Shibin, Gabelli, Sandra B., Vogelstein, Bert, Kinzler, Kenneth W.

“…The therapeutic applications of antibodies are manifold and the emergence of SARS-CoV-2 provides a cogent example of the value of rapidly identifying…”
Get full text

Activation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CA by Kim, Jung-Sik, Lee, Carolyn, Bonifant, Challice L., Ressom, Habtom, Waldman, Todd

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Redirecting T cells to hematological malignancies with bispecific antibodies by Velasquez, Mireya Paulina, Bonifant, Challice L., Gottschalk, Stephen

“…There is a need to improve outcomes for patients with recurrent and/or refractory hematological malignancies. Immunotherapy holds the promise to meet this…”
Get full text

The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing by Riberdy, Janice M., Zhou, Sheng, Zheng, Fei, Kim, Young-In, Moore, Jennifer, Vaidya, Abishek, Throm, Robert E., Sykes, April, Sahr, Natasha, Bonifant, Challice L., Ryu, Byoung, Gottschalk, Stephen, Velasquez, Mireya Paulina

“…Chimeric antigen receptor (CAR) T cells targeting CD123, an acute myeloid leukemia (AML) antigen, hold the promise of improving outcomes for patients with…”
Get full text

Engineering builds multipotency for iPSC-NKs by Rahnama, Ruyan, Bonifant, Challice L.

Get full text

Gene-Based Natural Killer Cell Therapies for the Treatment of Pediatric Hematologic Malignancies by Rahnama, Ruyan, Christodoulou, Ilias, Bonifant, Challice L

“…Pediatric blood cancers are among the most common malignancies that afflict children. Intensive chemotherapy is not curative in many cases, and novel therapies…”
Get full text

Programmed cell death protein 1 activation preferentially inhibits CD28.CAR–T cells by Zolov, Sergey N, Rietberg, Skyler P, Bonifant, Challice L

“…Abstract Targeted adoptive immunotherapy with engineered T cells is a promising treatment for refractory hematologic malignancies. However, many patients…”
Get full text

The future of cellular immunotherapy for childhood leukemia by Bonifant, Challice L., Tasian, Sarah K.

“…Exciting translational discoveries in recent years have brought realized promise of immunotherapy for children with high-risk leukemias. This review summarizes…”
Get full text

Improving CAR T-cells: The next generation by Marple, Andrew H., Bonifant, Challice L., Shah, Nirali N.

“…The introduction of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL) has dramatically altered the landscape of treatment…”
Get full text

CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia by Bonifant, Challice L, Szoor, Arpad, Torres, David, Joseph, Nicholos, Velasquez, Mireya Paulina, Iwahori, Kota, Gaikwad, Amos, Nguyen, Phuong, Arber, Caroline, Song, Xiao-Tong, Redell, Michele, Gottschalk, Stephen

“…Immunotherapy with CD123-specific T-cell engager proteins or with T cells expressing CD123-specific chimeric antigen receptors is actively being pursued for…”
Get full text

Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities by Christodoulou, Ilias, Ho, Won Jin, Marple, Andrew, Ravich, Jonas W, Tam, Ada, Rahnama, Ruyan, Fearnow, Adam, Rietberg, Cambrynne, Yanik, Sean, Solomou, Elena E, Varadhan, Ravi, Koldobskiy, Michael A, Bonifant, Challice L

“…BackgroundThe prognosis of patients with recurrent/refractory acute myelogenous leukemia (AML) remains poor and cell-based immunotherapies hold promise to…”
Get full text

Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation by Liu, Jie, Li, Chengxiu, Qu, Wei, Leslie, Elaine, Bonifant, Challice L, Buzard, Gregory S, Saavedra, Joseph E, Keefer, Larry K, Waalkes, Michael P

“…Development of chemotherapeutic resistance is a major cause of pharmacologic failure in cancer treatment. One mechanism of resistance in tumor cells is the…”
Get full text

Advances in immunotherapy for pediatric acute myeloid leukemia by Bonifant, Challice L, Velasquez, Mireya Paulina, Gottschalk, Stephen

“…Achieving better disease control in patients diagnosed with acute myeloid leukemia (AML) has proven challenging. Overall survival has been impacted by…”
Get more information

T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies by Velasquez, Mireya Paulina, Torres, David, Iwahori, Kota, Kakarla, Sunitha, Arber, Caroline, Rodriguez-Cruz, Tania, Szoor, Arpad, Bonifant, Challice L., Gerken, Claudia, Cooper, Laurence J. N., Song, Xiao-Tong, Gottschalk, Stephen

“…T cells expressing chimeric antigen receptors (CARs) or the infusion of bispecific T-cell engagers (BITEs) have shown antitumor activity in humans for…”
Get full text

Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel by Ravich, Jonas W., Huang, Sujuan, Zhou, Yinmei, Brown, Patrick, Pui, Ching-Hon, Inaba, Hiroto, Cheng, Cheng, Gottschalk, Stephen, Triplett, Brandon M., Bonifant, Challice L., Talleur, Aimee C.

“…CD19-specific chimeric antigen receptor (CAR) T-cell therapies, including the FDA–approved tisagenlecleucel, induce high rates of remission in pediatric…”
Get full text